Astellas And Pfizer To End Japan Co-Promotion Of Caduet
This article was originally published in PharmAsia News
Executive Summary
Astellas and Pfizer have agreed to end their co-promotion of the combination calcium antagonist/statin agent Caduet (amlodipine besylate/atorvastatin calcium hydrate) in Japan on March 21, 2015.